Gamida Cell $40MM Financing to support its Phase 3 Trial

Israel Biotech Fund participated in Gamida Cell’s $40MM financing round which shall support the ongoing Phase 3 trial of the its FDA Breakthrough Designated clinical-stage product, NiCord, to facilitate bone marrow transplantation. Read the full Article